Exclusive-AbbVie nears roughly $8 billion deal for drug developer Cerevel-sources
Tweet
Share
E-mail
FILE PHOTO: Test tubes are seen in front of a displayed Abbvie logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo
By David Carnevali
NEW YORK (Reuters) - AbbVie Inc is nearing an approximately $8 billion deal to acquire Cerevel Therapeutics Holdings Inc, a developer of drugs for neurological conditions such as Parkinson's, people familiar with the matter said on Wednesday.
The acquisition would come just days after AbbVie agreed to buy cancer drug developer ImmunoGen Inc for $10.1 billion in cash, highlighting its appetite to place big bets on promising new medicines.
AbbVie is in talks to pay around $45 per share for Cerevel, which is backed by private equity firm Bain Capital, the sources said.
If the negotiations conclude successfully, a deal could be announced as early as this week, the sources added, requesting anonymity because the matter is confidential.
AbbVie and Cerevel did not immediately respond to requests for comment.
Cerevel shares jumped 14% to $42.20 in afterhours trading in New York on Wednesday.
(Reporting by David Carnevali in New York; Editing by Greg Roumeliotis)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delivery Hero boards recommend Uber's €41.50-per-share takeover offer
- GoPro to merge with Starman Optical in $285M recapitalization deal
- LTC Properties buys four Minnesota senior communities for $200M
Create E-mail Alert Related Categories
Hot M&A, Mergers and Acquisitions, Reuters, RumorsRelated Entities
Bain Capital, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
